Jacobson Pharma Corporation Limited (Stock Code: 2633) announced its interim results for the six months ended 30 September 2025. Revenue was approximately HK$766.6 million, a 5.4% decrease compared to HK$810.0 million in the corresponding period of 2024. Profit from operations reached about HK$183.4 million, down 6.3% from HK$195.8 million last year.

Notably, profit attributable to equity shareholders rose by around 1.2% to HK$142.0 million, compared to HK$140.3 million a year ago. Management attributed the softened revenue to an early end to the flu season but noted that strong demand for chronic disease medications supported overall performance.

The board declared an interim dividend of HK4.25 cents per Share, representing a 21.4% increase from HK3.50 cents in 2024. Ongoing enhancements in manufacturing capacity, research and development advancements, and strategic partnerships are expected to further support the company’s competitiveness in the healthcare sector in Hong Kong and selected Asian markets.